HEALTHCARE

Teva had been in talks to sell its active pharmaceutical ingredients activity but a deal never materialized.

Former Teva CEO Jeremy Levin has published a sobering critique of a critical industry. He talks to "Globes" about his conclusions, and how Israel should act.

Dr. Marc Abitbol, who founded Jerusalem-based Visionix in 1994, tells “Globes” why he has finally decided to sell the eye care company and step down as CEO.

The company’s share price opened 22% higher today on Wall Street, giving a market cap of $984.5 million.

Reichman University’s Prof. Yosi Shacham-Diamand is developing chips that monitor plants, detect hazards in drinking water, and help medical teams treat wounded soldiers. Now he has an ambitious new vision.

In June 2025, an Iranian missile hit the Beersheva hospital's surgical wing, causing huge damage. The new plan includes three 30-floor towers.

The medical device company has developed an implant to protect healthy tissue from radiation damage during prostate cancer treatment.

The pharmaceutical company, controlled by FIMI, is one of the oldest in the Israeli economy.

The Israeli-German company has expanded from quantum sensing into quantum computing, advancing its efforts to build an end to end, quantum based approach to designing and validating therapies.

The Jerusalem hospital will be renamed the Koum Shaare Zedek Medical Center.

Dr. Henry and Dr. Susan Samueli have given $50 million to the Samueli Integrative Cancer Pioneering Institute at the hospital, following their initial $25 million donation to found the institute.
in the photo: Dr. Henry Samueli, Dr. Susan Samueli, Clalit Health Fund CEO Dr. Eitan Wertheim, and Prof. Gal Markel  credit: Koby Kuankas

The Israeli company analyzes more than 60 million patient cases annually in nearly 2,000 hospitals.

The Israeli pharmaceutical company has also announced first quarter results, which beat the analysts’ predictions.

The new agreement is a continuation of a collaboration between the parties, in which Ichilov transferred all of its computer systems to the cloud, becoming one of the world’s first hospitals to do so.

The company, which is building a new clinical infrastructure designed to close one of healthcare’s most costly and overlooked gaps, the 30 days following hospital discharge, has raised $20 million to date.

“Globes” interviews Eilat medical school Dean Prof. Hana Leiba about the country’s newest medical school, which is due to launch in October.

Even in wartime Israel’s healthcare system has shown resilience, reflecting a deeper structural strength that is increasingly capturing the attention of global healthcare investors.

Epitomee Medical has a distribution agreement with a German company, and has already begun sales in Israel.

United Health Services will pay $5.25 per share for the online and mobile therapy company.

Four Israeli hospitals are ranked by “Newsweek” in the world’s top 250.

The company identifies, through an AI-based discovery platform, new radiotherapy drugs that could be effective.

The US biotech company will pay $149 million including milestone payments for the Rehovot-based cancer testing company.

Acting under the radar in the US, the Israeli company is revolutionizing orthopedic medicine and bone healing by introducing innovative fiber materials.

Novocure's share price jumped after it announced FDA approval for its device for treating pancreatic cancer with electric fields.

The medical devices giant will pay $585 million immediately for the company and with milestone payments the deal could reach $1 billion.

As the control battle for the aesthetic medicine company heats up, co-founder and CEO Moshe Mizrahy blasts activist investors and backs the employees.

After three consecutive years of growth, the Israeli pharmaceutical company predicts a small decline this year.

The Israeli company has developed an implant to protect healthy tissue from radiation damage.

American-Iranian investor Amir Heshmatpour made his fortune in US biotech companies. He’s now in Israel with NeOnc, developer of a nasally administered brain cancer drug.

An article published in “Nature” presents a new model that can predict the risk of diabetes 12 years in advance, based on data collected from continuous glucose monitoring.